[Edaily Reporter Kwon Oh Seok ] SELVAS Healthcare, Inc.(208370)and OSANG HEALTHCARE CO.,LTD(036220)are showing strength during today’s trading session. It is noteworthy that both companies are expanding their business scope by integrating artificial intelligence (AI) diagnostic solutions and next-generation diagnostic devices into their existing medical device and in vitro diagnostics businesses. (Photo courtesy of SELVAS Healthcare, Inc.) According to MP Doctor on the 5th, as of 11:16 a.m., SELVAS Healthcare, Inc. is trading at 2,445 won, up 15.60% from the previous trading day, while OSANG HEALTHCARE CO.,LTD is trading at 5,450 won, up 7.07%. Intraday trading volume exceeded 5.5 million shares and 1.1 million shares, respectively. SELVAS Healthcare, Inc. is expanding its AI-based diagnostic and management solutions business by leveraging its existing medical device manufacturing capabilities, such as the body composition analyzer “ACCUNIQ” and hospital-grade blood pressure monitors. The company has established a joint venture, Selvas Invision, with UltraSight, a global AI echocardiography firm, and is currently pursuing the commercialization of related solutions in the domestic market. A flagship product is the AI echocardiography solution “UltraSight AI Guidance.” This product has obtained Class 2 digital medical device certification in South Korea. The technology uses AI to provide real-time guidance during the acquisition of echocardiography images, thereby reducing variations caused by differences in medical professionals’ proficiency and improving access to diagnosis. The company is also expanding its AI business into the chronic disease management sector. As a collaborating institution in the Korean ARPA-H project led by Chungnam National University Hospital, it has begun developing a platform that utilizes wearable devices and AI for the early detection of chronic kidney disease and the prevention of acute exacerbations. O’Sang Healthcare is broadening its business portfolio beyond its existing medical device operations to include AI-based chronic disease management. OSANG HEALTHCARE CO.,LTD is expanding its next-generation diagnostic device business based on its global in vitro diagnostics distribution network. While leveraging its overseas distribution network—established in over 100 countries—to expand the supply of existing diagnostic products, the company is also fostering point-of-care molecular diagnostics and continuous glucose monitors (CGMs) as new growth engines. In the field of point-of-care molecular diagnostics, the company is collaborating with U.S.-based Cryptos Biotechnology to develop PCR (polymerase chain reaction)-based diagnostic devices. Through clinical trials and the pursuit of U.S. Food and Drug Administration (FDA) approval, the company aims to expand its business scope from its existing focus on immunoassays into the molecular diagnostics sector. In the CGM sector, the company is advancing commercialization based on a strategic investment in the U.S. development firm Allez Health. It is also working to secure a domestic production base for related products and preparing to enter the next-generation blood glucose management market. The company has also achieved success in overseas supply within its existing diagnostics business. Through HemoCue AB, a global point-of-care diagnostics company, it has signed a contract to supply HbA1c meters and cartridges to the Mexican government’s public healthcare procurement market. The contract is valued at approximately 6.5 billion won, and the company plans to supply products over the next two years.
As the spread of fraud and misinformation using artificial intelligence (AI) continues to rise, investment is flowing into European startups that verify AI-generated content. The scope of investment i…
“Limcato,” developed by Curocell Inc. and Korea’s first domestically produced chimeric antigen receptor T-cell (CAR-T) therapy, is set to be covered by the National Health Insurance. This is expected …
CJ ENM CO., Ltd.(035760)has filed a petition for a preliminary injunction with the court, asking it to prevent LG HelloVision(037560)from suspending broadcasts on its four channels.
(Photo: CJ ENM …